INOVIO Announces Proposed Public Offering

Rhea-AI Summary

INOVIO (NASDAQ: INO) announced a proposed underwritten public offering of common stock and accompanying Series A and Series B warrants (or pre-funded warrants) to purchase common stock.

The company said it will sell all securities offered, grant a 30-day underwriter option for up to 15% additional securities, and named Piper Sandler as sole manager. The offering is subject to market conditions and may not be completed.

Positive

• Underwriter option up to 15% additional securities
• Piper Sandler appointed sole manager for the offering
• Company sells all offered securities, indicating direct capital raise

Negative

• Potential dilution to existing shareholders from new shares and warrants
• Completion uncertain because offering is subject to market conditions
• No offering size disclosed, leaving financing magnitude unclear

Key Figures

Underwriter option period: 30 days Underwriter option size: 15% of securities Shelf filing date: November 9, 2023 +5 more

8 metrics

Underwriter option period 30 days Option for additional shares and warrants in this offering

Underwriter option size 15% of securities Potential extra common stock and warrants in the deal

Shelf filing date November 9, 2023 Registration statement referenced in the offering press release

Shelf effective date January 31, 2024 Date SEC declared the registration statement effective

Current share price $1.74 Price before the April 1, 2026 offering announcement

52-week high discount -41.59% Price vs. 52-week high of $2.9789 before the news

52-week low premium 33.85% Price vs. 52-week low of $1.30 before the news

Market cap $120,220,003 Equity value before the proposed April 2026 offering

Market Reality Check

Price: $1.7400 Vol: Volume 525,093 is about 3...

low vol

$1.7400 Last Close

Volume Volume 525,093 is about 34% below the 20-day average of 793,983, indicating muted trading ahead of the proposed deal. low

Technical Shares at $1.74 are trading below the 200-day MA of $1.93 and about 41.59% under the 52-week high.

Peers on Argus

INO was flat pre-announcement while momentum scanners showed biotech peers like ...

2 Up

INO was flat pre-announcement while momentum scanners showed biotech peers like TARA and CABA moving up. Mixed peer moves and unchanged INO price suggest this proposed offering is a stock-specific catalyst rather than part of a broad sector rotation.

Previous Offering Reports

5 past events · Latest: Nov 11 (Negative)

Same Type Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Nov 11	Offering priced	Negative	-7.0%	Priced $25M stock offering at $1.90 with underwriter option.
Nov 10	Proposed offering	Negative	-7.0%	Announced intent to sell common stock in underwritten deal.
Jul 03	Offering priced	Negative	-37.9%	Priced $25M offering with 14.3M shares plus Series A/B warrants.
Jul 02	Proposed offering	Negative	-37.9%	Proposed stock and warrant financing with 15% underwriter option.
Dec 13	Offering priced	Negative	-38.3%	Announced pricing of $30M stock and warrant public offering.

Pattern Detected

Past 5 offering-related announcements all saw negative 24h moves, with an average reaction of about -25.59%, indicating a consistent pattern of shareholder concern around equity financings.

Recent Company History

Over the past year, INOVIO has repeatedly used public offerings of common stock and warrants to raise capital, often under the same November 9, 2023 registration. Prior proposed and priced offerings in December 2024, July 2025, and November 2025 all triggered double‑digit percentage declines, with an average move of -25.59%. Today’s proposed underwritten public offering of common stock and Series A/B (or pre‑funded) warrants fits this pattern of dilution-focused financing activity.

Historical Comparison

-25.6% avg move · INOVIO has issued 5 offering-related announcements since late 2024, with an average 24-hour move of ...

offering

-25.6%

Average Historical Move offering

INOVIO has issued 5 offering-related announcements since late 2024, with an average 24-hour move of -25.59%. The new proposed stock-and-warrant deal fits this established dilution-driven pattern.

The company has repeatedly relied on public offerings of common stock and warrants, often including underwriter 30-day options and Series A/B warrant structures, to finance operations.

Market Pulse Summary

This announcement details INOVIO’s plan for an underwritten public offering of common stock with Ser...

Analysis

This announcement details INOVIO’s plan for an underwritten public offering of common stock with Series A and Series B (or pre-funded) warrants and a 30-day option for 15% additional securities. Historically, similar offerings have coincided with negative short-term moves, averaging -25.59%. Investors may focus on how any proceeds interact with the company’s loss-making profile, pipeline milestones, and prior reliance on equity financings.

Key Terms

underwritten public offering, series a warrants, series b warrants, pre-funded warrants, +2 more

6 terms

underwritten public offering financial

"it intends to offer and sell shares of its common stock...in an underwritten public offering"

An underwritten public offering is when a company sells new shares of its stock to the public with the help of a financial firm, called an underwriter. The underwriter agrees to buy all the shares upfront, reducing the company's risk, and then sells them to investors. This process helps companies raise money quickly and confidently from a wide range of buyers.

series a warrants financial

"shares of its common stock and accompanying Series A warrants and Series B warrants"

Series A warrants are financial tools that give the holder the right to buy shares of a company at a specific price within a certain period. They are often issued alongside investments to provide additional potential profit if the company's value increases. For investors, they can offer a chance to benefit from future growth without committing immediate capital to buying shares.

series b warrants financial

"shares of its common stock and accompanying Series A warrants and Series B warrants"

Series B warrants are contracts issued alongside a company's Series B financing that give the holder the right to buy a set number of shares at a fixed price within a specified time. For investors, they matter because they can provide leveraged upside if the company grows, or they can dilute existing shareholders when exercised—like a coupon promising a future share at a known price that can add value or change ownership stakes.

pre-funded warrants financial

"or pre-funded warrants to purchase its common stock in lieu thereof"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

shelf registration statement regulatory

"A shelf registration statement relating to the shares of common stock and accompanying Series A and Series B warrants"

A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.

prospectus supplement regulatory

"A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

AI-generated analysis. Not financial advice.

PLYMOUTH MEETING, Pa., April 1, 2026 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it intends to offer and sell shares of its common stock and accompanying Series A warrants and Series B warrants to purchase shares of its common stock (or pre-funded warrants to purchase its common stock in lieu thereof), in an underwritten public offering. All of the securities in the proposed offering will be sold by INOVIO. INOVIO intends to grant the underwriter a 30-day option to purchase additional shares of its common stock and/or accompanying Series A and Series B warrants to purchase shares of its common stock in an amount up to 15% of the securities offered in the public offering under the same terms and conditions. The proposed offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.

Piper Sandler is acting as sole manager for the offering.

A shelf registration statement relating to the shares of common stock and accompanying Series A and Series B warrants offered in the offering described above was filed with the Securities and Exchange Commission ("SEC") on November 9, 2023 and declared effective by the SEC on January 31, 2024. The offering will be made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC's website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus, when available, may also be obtained by contacting: Piper Sandler & Co., 350 North 5th Street, Suite 1000, Minneapolis, Minnesota 55401, Attention: Prospectus Department, by telephone at (800) 747-3924, or by e-mail at prospectus@psc.com.  

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About INOVIO

INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools.

Forward-Looking Statements

This release contains or may imply "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not based on historical fact and include, but are not limited to, statements regarding INOVIO's anticipated public offering, including the completion of the public offering on the anticipated terms, if at all, and INOVIO's plans to grant the underwriter a 30-day option to purchase additional shares and warrants. Any forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties related to market conditions and satisfaction of customary closing conditions related to the proposed public offering. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in INOVIO's Annual Report on Form 10-K for the year ended December 31, 2025 and in other filings that INOVIO makes with the SEC from time to time. There can be no assurance that any of the forward-looking information provided herein will be proven accurate. These forward-looking statements speak only as of the date hereof and INOVIO undertakes no obligation to update forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements.

Contacts

Media: Jennie Willson (267) 429-8567 jennie.willson@inovio.com
Investors: Peter Vozzo, ICR Healthcare, 443-213-0505 peter.vozzo@icrhealthcare.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/inovio-announces-proposed-public-offering-302732135.html

SOURCE INOVIO Pharmaceuticals, Inc.

FAQ

What securities is INOVIO (INO) proposing to offer in April 2026?

INOVIO proposes to offer common stock plus Series A and Series B warrants (or pre-funded warrants). According to INOVIO, all offered securities will be sold by the company in an underwritten public offering with a preliminary prospectus to be filed.

How large is the underwriter option in INOVIO's proposed offering (INO)?

The underwriter has a 30-day option to purchase up to 15% additional securities. According to INOVIO, that option covers additional common stock and accompanying Series A and Series B warrants on the same terms.

Who is managing INOVIO's (INO) proposed public offering?

Piper Sandler is acting as sole manager for the offering. According to INOVIO, inquiries and prospectus requests can be directed to Piper Sandler's prospectus department as listed in the announcement.

Will INOVIO's (INO) proposed offering definitely proceed and when will details be available?

The offering is not guaranteed and is subject to market conditions and timing. According to INOVIO, a preliminary prospectus supplement and prospectus describing terms will be filed with the SEC and made available when ready.

Will INOVIO (INO) sell the securities itself or are existing holders selling shares?

INOVIO stated that all securities in the proposed offering will be sold by the company. According to INOVIO, no existing holders are listed as selling; proceeds would flow to the company.

How can investors obtain INOVIO's (INO) preliminary prospectus for the offering?

Investors can obtain the preliminary prospectus from the SEC website or Piper Sandler. According to INOVIO, the prospectus supplement will be filed with the SEC and available at www.sec.gov and via Piper Sandler contact details.